| Trial ID: | L2057 |
| Source ID: | NCT01102673
|
| Associated Drug: |
Pf-04991532
|
| Title: |
Single Dose Study of PF-04991532 in Healthy Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders
|
| Interventions: |
DRUG: PF-04991532|DRUG: Placebo
|
| Outcome Measures: |
Primary: Safety and Tolerability Endpoints: physical exams, AE monitoring, 12-lead ECGs, continuous cardiac monitoring, vital sign and clinical safety laboratory (including frequent glucose assessments via glucometer) measurements., 1 month|PK Endpoints: AUC(0-inf), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit., 1 month | Secondary: none-see my comment
|
| Sponsor/Collaborators: |
Sponsor: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose:
|
| Start Date: |
2010-04
|
| Completion Date: |
2010-06
|
| Results First Posted: |
|
| Last Update Posted: |
2010-08-05
|
| Locations: |
Pfizer Investigational Site, New Haven, Connecticut, 06511, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01102673
|
